Abstract: A health management system and a health management method are provided. The health management method includes: measuring a position information of a person; determining to measure a physiological state information of the person according to the position information; and generating a physiological state report according to the physiological state information.

Abstract: A method for treating cancer in a subject is provided; the method includes administrating bupropion to the subject, wherein the tumor cells of the cancer overexpress neuronal acetylcholine receptor subunit ?9 (CHRNA9). Another method for treating cancer in a subject is provided; the method includes administrating a pharmaceutical composition to the subject, wherein the pharmaceutical composition includes: a therapeutically effective amount of bupropion and a pharmaceutically acceptable excipient; wherein the tumor cells of the cancer overexpress CHRNA9. A method for inhibiting migration of tumor cells is also provided; the method includes administrating an effective amount of bupropion to the tumor cells; wherein the tumor cells overexpress CHRNA9.

Abstract: An OLED (organic light-emitting diode) pixel structure comprises a substrate, first and second control components, first, second, and complementary electrode layers, and first and second light-emitting layers. The first and second control components are disposed above the substrate and electrically coupled to, respectively, the first and second electrode layers. There are first and second neighborhoods defined in the pixel structure, and the substrate traverses both of the neighborhoods. The first electrode layer is disposed in the first neighborhood and comprises a reflective layer. The first light-emitting layer is disposed on and electrically coupled to the first electrode layer. The second electrode layer is transparent and disposed in the second neighborhood. The second light-emitting layer is disposed on and electrically coupled to the second electrode layer. The complementary electrode layer is disposed on and electrically coupled to the light-emitting layers.

Abstract: An OLED (organic light-emitting diode) pixel structure comprises a substrate, first and second control components, first, second, and complementary electrode layers, and first and second light-emitting layers. The first and second control components are disposed above the substrate and electrically coupled to, respectively, the first and second electrode layers. There are first and second neighborhoods defined in the pixel structure, and the substrate traverses both of the neighborhoods. The first electrode layer is disposed in the first neighborhood and comprises a reflective layer. The first light-emitting layer is disposed on and electrically coupled to the first electrode layer. The second electrode layer is transparent and disposed in the second neighborhood. The second light-emitting layer is disposed on and electrically coupled to the second electrode layer. The complementary electrode layer is disposed on and electrically coupled to the light-emitting layers.

Abstract: A display panel uses demultiplexers to reduce numbers of data lines, and divides the data lines into groups being coupled to the demultiplexers respectively. The demultiplexers are disposed along an edge of the display region and compliant to the outline of the display panel, so as to save the layout space. In addition, the layout of control lines of the demultiplexers can be configured to more effectively utilize the layout space in the layout region. Furthermore, the aforementioned layout helps reduce the length of the conductive lines, and improves the transmission of signals in the conductive lines.

Abstract: A transparent display panel including a transparent substrate and a plurality of display units formed on the substrate is provided. Each of the display units includes a color light area and a least one of transparent areas disposed around the color light area. The color light area has a geometric center, a first color pixel structure, a second color pixel structure, and a third color pixel structure. The first, second and third color pixel structures take the geometric center as a center in each display unit and are disposed in a radial way corresponding to the center to form the color light area.

Abstract: A light emitting device including a plurality of units is provided. Each unit includes a light emitting region and a light-transmitting region, wherein in at least one unit, at least two sides of the light emitting region are surrounded by the light-transmitting region.

Abstract: A display panel uses demultiplexers to reduce numbers of data lines, and divides the data lines into groups being coupled to the demultiplexers respectively. The demultiplexers are disposed along an edge of the display region and compliant to the outline of the display panel, so as to save the layout space. In addition, the layout of control lines of the demultiplexers can be configured to more effectively utilize the layout space in the layout region. Furthermore, the aforementioned layout helps reduce the length of the conductive lines, and improves the transmission of signals in the conductive lines.

Abstract: A method for manufacturing an organic light emitting display panel is disclosed. The organic light emitting display panel includes a substrate. The method includes forming a plurality of bank arrays, each of which has a plurality of banks, utilizing a plurality of ink-jet heads, each of which has a plurality of nozzles arranged alternately, to move relative to the substrate along a moving direction perpendicular to a border of the substrate, and utilizing at least one of the plurality of nozzles to drop organic light emitting ink for forming at least one organic light emitting pixel in at least one bank. An oblique angle is formed between an arrangement direction of the plurality of banks and the border of the substrate. Each ink-jet head forms the oblique angle cooperatively with the border of the substrate.

Abstract: An OLED (organic light-emitting diode) pixel structure comprises a substrate, first and second control components, first, second, and complementary electrode layers, and first and second light-emitting layers. The first and second control components are disposed above the substrate and electrically coupled to, respectively, the first and second electrode layers. There are first and second neighborhoods defined in the pixel structure, and the substrate traverses both of the neighborhoods. The first electrode layer is disposed in the first neighborhood and comprises a reflective layer. The first light-emitting layer is disposed on and electrically coupled to the first electrode layer. The second electrode layer is transparent and disposed in the second neighborhood. The second light-emitting layer is disposed on and electrically coupled to the second electrode layer. The complementary electrode layer is disposed on and electrically coupled to the light-emitting layers.

Abstract: A transparent display panel including a transparent substrate and a plurality of display units formed on the substrate is provided. Each of the display units includes a color light area and a least one of transparent areas disposed around the color light area. The color light area has a geometric center, a first color pixel structure, a second color pixel structure, and a third color pixel structure. The first, second and third color pixel structures take the geometric center as a center in each display unit and are disposed in a radial way corresponding to the center to form the color light area.

Abstract: A light emitting device including a plurality of units is provided. Each unit includes a light emitting region and a light-transmitting region, wherein in at least one unit, at least two sides of the light emitting region are surrounded by the light-transmitting region.

Abstract: The invention relates to methods of identifying a candidate compound which may inhibit estrogen receptor-dependent transcription or ?9-nAChR overexpression and proliferation of nicotine-derived-compound-induced breast cancer cells by using an activating protein 1 (AP1) polypeptide. The invention found that ?9-nAChR has an activating protein 1 (AP1)-binding site, that the ?9-nAChR promoter is located at the AP1-binding site, and that ERs specifically bind to the ?9-nAChR promoter at the AP1-binding site, indicating that ER-induced ?9-nAChR up-regulation plays a central role in the response to endogenous (E2) or exogenous (nicotine) stimulation.

Abstract: A method for manufacturing an organic light emitting display panel is disclosed. The organic light emitting display panel includes a substrate. The method includes forming a plurality of bank arrays, each of which has a plurality of banks, utilizing a plurality of ink-jet heads, each of which has a plurality of nozzles arranged alternately, to move relative to the substrate along a moving direction perpendicular to a border of the substrate, and utilizing at least one of the plurality of nozzles to drop organic light emitting ink for forming at least one organic light emitting pixel in at least one bank. An oblique angle is formed between an arrangement direction of the plurality of banks and the border of the substrate. Each ink-jet head forms the oblique angle cooperatively with the border of the substrate.

Abstract: The invention found that overexpression and activation of ?9-nAChR are associated with tumorigenesis of breast cancer and create a number of small interfering RNAs to inhibit the expression of ?9-nAChR so as to inhibit breast cancer. Therefore, the invention provides small interfering RNAs (siRNAs) for inhibiting expression of ?9-nAChR so as to inhibit breast cancer, methods to prevent/inhibit/treat malignant progression of nicotine-derived-compound-induced breast cancer and method of determining malignant level of such breast cancer.

Abstract: The invention relates to methods of identifying a candidate compound which may inhibit estrogen receptor-dependent transcription or ?9-nAChR overexpression and proliferation of nicotine-derived-compound-induced breast cancer cells by using an activating protein 1 (AP1) polypeptide. The invention found that ?9-nAChR has an activating protein 1 (AP1)-binding site, that the ?9-nAChR promoter is located at the AP1-binding site, and that ERs specifically bind to the ?9-nAChR promoter at the AP1-binding site, indicating that ER-induced ?9-nAChR up-regulation plays a central role in the response to endogenous (E2) or exogenous (nicotine) stimulation.

Abstract: The invention found that overexpression and activation of ?9-nAChR are associated with tumorigenesis of breast cancer and create a number of small interfering RNAs to inhibit the expression of ?9-nAChR so as to inhibit breast cancer. Therefore, the invention provides small interfering RNAs (siRNAs) for inhibiting expression of ?9-nAChR so as to inhibit breast cancer, methods to prevent/inhibit/treat malignant progression of nicotine-derived-compound-induced breast cancer and method of determining malignant level of such breast cancer.

Abstract: This invention relates to methods of aiding smoking cessation and/or treating and/or preventing smoking addition or methods of treating and/or preventing nicotine or nicotine-derived compounds or estrogen induced breast cancer, which comprises administering to a subject an effective amount of a tea polyphenol. The invention uses catechins (such as epigallocatechin gallate (“EGCG”), epigallocatechin (“EGC”), epicatechin gallate (“ECG”), epicatechin (“EC”), gallocatechin gallate (“GCG”), gallocatechin (“GC”), catechin gallate (“CG”) and catechin (“C”)) in aiding smoking cessation and/or treating and/or preventing smoking addition or treating and/or preventing nicotine or nicotine-derived compounds or estrogen induced breast cancer.

Abstract: This invention relates to methods of treating and/or preventing nicotine or nicotine-derived compounds or estrogen induced breast cancer, which comprises administering to a subject an effective amount of a tea polyphenol. The invention uses catechins (such as epigallocatechin gallate (“EGCG”), epigallocatechin (“EGC”), epicatechin gallate (“ECG”), epicatechin (“EC”), gallocatechin gallate (“GCG”), gallocatechin (“GC”), catechin gallate (“CG”) and catechin (“C”)) in treating and/or preventing nicotine or nicotine-derived compounds or estrogen induced breast cancer.

Abstract: A network telephone system for recovering talk after an unexpected disconnection and a method thereof are used to recover an unexpectedly disconnected talk between network telephones. The network telephone system includes a central processing unit, a talk database, a real-time transport protocol (RTP) buffer, and a network module. A method for recovering talk after an unexpected disconnection includes: recording and storing information of the network telephone in a talk state; judging whether an unexpected disconnection of talk occurs by checking that the network is disconnected or no RTP packet exists; and re-establishing talk by inquiring the network telephone information of a current talk.